Oral Session 1-10C AML: FLT3 Inhibitors

[OS1-10C-4] Phase I result of quizartinib with intensive chemotherapy in newly-diagnosed Japanese AML patients

Ilseung Choi¹, Shuichi Ota², Satoshi Ichikawa³, Naohito Fujishima⁴, Hiroatsu Iida⁵, Isamu Sugiura⁶, Koichi Sugiura⁷, Masaya Tachibana⁷, Shoichi Ohwada⁷, Daisuke Kuroki⁷, Sakura Sakajiri⁸ (1.National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 2.Sapporo Hokuyu Hospital, Sapporo, Japan, 3.Tohoku University Hospital, Sendai, Japan, 4.Akita University Hospital, Akita, Japan, 5.National Hospital Organization Nagoya Medical Center, Nagoya, Japan, 6.Toyohashi Municipal Hospital, Toyohashi, Japan, 7.Daiichi Sankyo Co., Ltd., Tokyo, Japan, 8.Juntendo University Urayasu Hospital, Urayasu, Japan)